How do you approach treatment for patients with ALK+ mNSCLC who have multifocal or leptomeningeal CNS progression while on first-line targeted therapy?   

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?



Answer from: Medical Oncologist at Academic Institution
Comments
Radiation Oncologist at Lafayette Radiation Center
Crainiospinal irradiation (CSI) is extremely toxic...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice